Antibodies generated by COVID-19 infection or vaccination show a cross-reactive capacity to neutralize related bat coronaviruses, according to new research published in the journal PLOS Biology. While these findings, reported by Earth.com, demonstrate that human immunity may offer a layer of protection against emerging zoonotic threats, the potential efficacy against future spillover events remains a laboratory-based observation rather than a clinical certainty.
SARS-CoV-2 Antibodies Neutralize Similar Bat Viruses
- Broadened Immunity: Antibodies produced against SARS-CoV-2 do not just target the primary virus; they can recognize and neutralize “cousin” viruses found in bats, provided those viruses share structural similarities.
- The “Specialist” vs. “Generalist” Virus: Viruses that utilize the ACE2 receptor across multiple species are more susceptible to these existing antibodies, as they share key antigenic regions with SARS-CoV-2.
- Laboratory Models: This research utilized “pseudotypes”—harmless viral stand-ins carrying the coronavirus spike protein—to test immune response, meaning these results represent a controlled, in-vitro simulation rather than a real-world infection scenario.
Researchers Analyze How Coronaviruses Bind to ACE2 Proteins
The research team, led by Nazia Thakur, a postdoctoral scientist at The Pirbright Institute, in collaboration with King’s College London, explored how specific coronaviruses infiltrate cells. A virus gains entry by binding to the ACE2 (angiotensin-converting enzyme 2) protein on the surface of a host cell. Because different species possess slightly different versions of the ACE2 protein, a virus is often limited to a specific host range.
The study analyzed 15 bat coronaviruses, testing their spike proteins against ACE2 receptors from 16 bat species and 18 other mammals, including humans, pangolins, and raccoon dogs. The results revealed that viruses within the same family branch as SARS-CoV-2—such as the BANAL viruses identified in bats in Laos—demonstrated a “generalist” ability to bind to various species’ receptors. Conversely, more distant relatives of SARS-CoV-2 were “specialists,” restricted to the ACE2 receptors of only a limited range of hosts.
Thakur noted in her interview with Earth.com that the difference between a highly versatile virus and a restricted one often comes down to only a few key regions within the viral spike. Even closely related viruses, such as RaTG13, showed more restricted receptor usage than SARS-CoV-2, highlighting that evolutionary proximity does not always guarantee the same biological behavior.
Neutralization Capacity of COVID-19 Antibodies
To determine if existing human immunity provides a protective barrier, the researchers exposed these bat coronavirus spikes to plasma and serum from individuals who had recovered from various SARS-CoV-2 variants, including Alpha, Gamma, Delta, and Omicron BA.1. The study also included pooled plasma from vaccinated individuals.
The antibodies exhibited the strongest neutralization against viruses within the SARS-CoV-2 branch. While efficacy waned against more distantly related bat viruses, the immune response did not completely fail. Katie Doores, professor of viral immunology at King’s College London, emphasized that these bat viruses showed a clear “antigenic similarity” to SARS-CoV-2, which is the primary reason the human immune system is able to recognize and neutralize them.
| Viral Category | Receptor Versatility | Neutralization Potential |
|---|---|---|
| SARS-CoV-2 Branch | High (Multi-species) | Strong |
| Intermediate Relatives | Moderate | Moderate |
| Distant Specialists | Low (Host-specific) | Weak |
Vaccination Does Not Grant Absolute Immunity to Novel Pathogens
It is vital to distinguish between laboratory-based antibody neutralization and clinical immunity. This study does not suggest that COVID-19 vaccination acts as a universal prophylactic against all future coronaviruses. Patients should not assume that past infection or vaccination grants absolute immunity to novel zoonotic pathogens.
Findings Help Scientists Prioritize High Risk Bat Coronaviruses
The findings provide a roadmap for public health surveillance, helping scientists prioritize which bat coronaviruses represent the highest risk for human spillover. By identifying which viruses are most “recognized” by existing human antibodies, researchers can narrow their focus to those that might successfully establish themselves in human populations.
The scientific community continues to monitor viral evolution, particularly as SARS-CoV-2 variants like Omicron demonstrate shifts in their ability to bind to different host receptors. While widespread exposure to SARS-CoV-2 may have created a baseline of cross-reactive immunity, the transition from a cave-dwelling virus to a human pathogen still requires significant environmental and biological factors, such as those found in the wildlife trade. The next step for the research team involves testing plasma against a wider array of bat coronaviruses to refine the understanding of this potential protective barrier.
